EC
PROK icon

EntryPoint Capital’s ProKidney PROK Stock Holding History

EntryPoint Capital’s Portfolio PROK Stock Details PROK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$148K Buy
82,862
+54,045
+188% +$115K 0.04% 677
2025
Q4 		$64.5K Buy
+28,817
New +$75.8K 0.03% 626
2024
Q4 		– Sell
-16,998
Closed -$32.6K – 918
2024
Q3 		$32.6K Buy
+16,998
New +$38.6K 0.02% 592

Other funds holding PROK

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
AGP
Artia Global Partners Miami, Florida $499M AUM 186.05% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

EntryPoint Capital's PROK Position: Q1 2026 in Review

EntryPoint Capital increased its ProKidney (PROK) stake by 188% in Q1 2026, buying an estimated $115K and bringing the position to 82,862 shares worth $148K. The position accounts for 0.04% of the portfolio, ranked #677.

EntryPoint Capital first reported a position in PROK in Q3 2024 and has held it in 3 quarters since. 71 funds tracked by Wall St. Rank hold PROK as of Q1 2026.

  • EntryPoint Capital held 82,862 shares of ProKidney worth $148K as of Q1 2026.
  • EntryPoint Capital bought 54,045 ProKidney shares in Q1 2026, an estimated $115K.
  • ProKidney made up 0.04% of EntryPoint Capital's portfolio in Q1 2026, its #677 holding.
  • EntryPoint Capital first reported a position in ProKidney in Q3 2024 and has held it in 3 quarters since.
  • 71 funds tracked by Wall St. Rank held ProKidney as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.